The Adipose Tissue-Derived Secretome (ADS) in Obesity Uniquely Induces L-Type Amino Acid Transporter 1 (LAT1) and mTOR Signaling in Estrogen-Receptor-Positive Breast Cancer Cells

被引:11
|
作者
Thompson, Chelsea [1 ,2 ]
Rahman, M. Motiur [2 ,3 ,4 ]
Singh, Soudamani [2 ,3 ,4 ]
Arthur, Subha [2 ,3 ,4 ]
Sierra-Bakhshi, Cecilia [1 ,2 ]
Russell, Rebecca [2 ,5 ]
Denning, Krista [2 ,5 ]
Sundaram, Uma [2 ,3 ,4 ]
Salisbury, Travis [1 ,2 ,3 ,4 ]
机构
[1] Marshall Univ, Joan C Edwards Sch Med, Dept Biomed Sci, Huntington, WV 25755 USA
[2] Marshall Univ, Joan C Edwards Sch Med, Appalachian Ctr Cellular Transport Obes Related D, 1600 Med Ctr Dr, Huntington, WV 25755 USA
[3] Marshall Univ, Joan C Edwards Sch Med, Dept Clin & Translat Sci, 1600 Med Ctr Dr, Huntington, WV 25701 USA
[4] Marshall Univ, Joan C Edwards Sch Med, Appalachian Clin & Translat Sci Inst, 1600 Med Ctr Dr, Huntington, WV 25701 USA
[5] Marshall Univ, Joan C Edwards Sch Med, Dept Pathol, Cabell Huntington Hosp Lab, Huntington, WV 25701 USA
基金
美国国家卫生研究院;
关键词
breast cancer; obesity; LAT1; leucine; mTOR; GROWTH; LEUCINE; METABOLISM; MECHANISMS; OVERWEIGHT; HETERODIMERS; 4F2HC/CD98; EXPRESSION; MDA-MB-231; PATHWAY;
D O I
10.3390/ijms22136706
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obesity increases the risk of postmenopausal breast cancer (BC). This risk is mediated by obesity-induced changes in the adipose-derived secretome (ADS). The pathogenesis of BC in obesity is stimulated by mTOR hyperactivity. In obesity, leucine might support mTOR hyperactivity. Leucine uptake by BC cells is through L-Type Amino Acid Transporter 1 (LAT1). Our objective was to link obesity-ADS induction of LAT1 to the induction of mTOR signaling. Lean- and obese-ADS were obtained from lean and obese mice, respectively. Breast ADS was obtained from BC patients. Estrogen-receptor-positive BC cells were stimulated with ADS. LAT1 activity was determined by uptake of H-3-leucine. The LAT1/CD98 complex, and mTOR signaling were assayed by Western blot. The LAT1 antagonists, BCH and JPH203, were used to inhibit LAT1. Cell migration and invasion were measured by Transwell assays. The results showed obese-ADS-induced LAT1 activity by increasing transporter affinity for leucine. Consistent with this mechanism, LAT1 and CD98 expression were unchanged. Induction of mTOR by obese-ADS was inhibited by LAT1 antagonists. Breast ADS from patients with BMIs > 30 stimulated BC cell migration and invasiveness. Collectively, our findings show that obese-ADS induction of LAT1 supports mTOR hyperactivity in luminal BC cells.
引用
收藏
页数:13
相关论文
共 32 条
  • [1] Immunohistochemical expression of L-type amino acid transporter 1(LAT1) for human breast cancer
    Uchigasaki, S
    Sakamoto, A
    JOURNAL OF PATHOLOGY, 2002, 198 : 57A - 57A
  • [2] The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer
    Salisbury, Travis B.
    Arthur, Subha
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [3] Positive Regulation of Decidualization by L-Type Amino Acid Transporter 1 (lat1) in Pregnant Mice
    Wang, Xiaojie
    Tan, Dongmei
    Ma, Jing
    Liang, Hao
    Zhang, Qian
    Tan, Yi
    Wang, Jiang
    Luo, Wenping
    NUTRIENTS, 2016, 8 (11)
  • [4] Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
    Sasagu Kurozumi
    Kyoichi Kaira
    Hiroshi Matsumoto
    Masafumi Kurosumi
    Takehiko Yokobori
    Yoshikatsu Kanai
    Chikako Sekine
    Chikako Honda
    Ayaka Katayama
    Mio Furuya
    Sho Shiino
    Takaya Makiguchi
    Nigel P. Mongan
    Emad A. Rakha
    Tetsunari Oyama
    Takaaki Fujii
    Ken Shirabe
    Jun Horiguchi
    Scientific Reports, 12
  • [5] Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
    Kurozumi, Sasagu
    Kaira, Kyoichi
    Matsumoto, Hiroshi
    Kurosumi, Masafumi
    Yokobori, Takehiko
    Kanai, Yoshikatsu
    Sekine, Chikako
    Honda, Chikako
    Katayama, Ayaka
    Furuya, Mio
    Shiino, Sho
    Makiguchi, Takaya
    Mongan, Nigel P.
    Rakha, Emad A.
    Oyama, Tetsunari
    Fujii, Takaaki
    Shirabe, Ken
    Horiguchi, Jun
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer
    Shindo, Haruhiko
    Harada-Shoji, Narumi
    Ebata, Akiko
    Sato, Miku
    Soga, Tomoyoshi
    Miyashita, Minoru
    Tada, Hiroshi
    Kawai, Masaaki
    Kosaka, Shinkichi
    Onuki, Koji
    Usami, Shin
    Furumoto, Shozo
    Hayashi, Shinichi
    Abe, Takaaki
    Suzuki, Takashi
    Ishida, Takanori
    Sasano, Hironobu
    CANCERS, 2021, 13 (17)
  • [7] Role of L-Type Amino Acid Transporter 1 (LAT1) for the Selective Cytotoxicity of Sesamol in Human Melanoma Cells
    Srisongkram, Tarapong
    Weerapreeyakul, Natthida
    Karkkainen, Jussi
    Rautio, Jarkko
    MOLECULES, 2019, 24 (21):
  • [8] L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells
    Satou, Motoyasu
    Wang, Jason
    Nakano-Tateno, Tae
    Teramachi, Mariko
    Suzuki, Tokiko
    Hayashi, Keitaro
    Lamothe, Shawn
    Hao, Yubin
    Kurata, Harley
    Sugimoto, Hiroyuki
    Chik, Constance
    Tateno, Toru
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2020, 515
  • [9] Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1)
    Kongpracha, Pornparn
    Nagamori, Shushi
    Wiriyasermkul, Pattama
    Tanaka, Yoko
    Kaneda, Kazuko
    Okuda, Suguru
    Ohgaki, Ryuichi
    Kanai, Yoshikatsu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 133 (02) : 96 - 102
  • [10] A Selective and Slowly Reversible Inhibitor of L-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells
    Huttunen, Kristiina M.
    Gynther, Mikko
    Huttunen, Johanna
    Puris, Elena
    Spicer, Julie A.
    Denny, William A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (12) : 5740 - 5751